1204669-63-5

Basic information

• Product Name: 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]-
• Synonyms: 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]-;4-(3-bromo-4-fluorophenyl)-3-[4-(2-methoxyethylamino)-1,2,5-oxadiazol-3-yl]-1,2,4-oxadiazol-5-one
• CAS NO: 1204669-63-5
• Molecular Formula: C₁₃H₁₁BrFN₅O₄
• Molecular Weight: 400.1599432
• Mol File: 1204669-63-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]-(1204669-63-5)
• EPA Substance Registry System: 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]-(1204669-63-5)

Safety Data

• Hazardous Substances Data: 1204669-63-5(Hazardous Substances Data)

Usage

General Description

1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]- is a chemical compound that contains both oxadiazole and oxadiazolinone moieties. It has a 4-(3-bromo-4-fluorophenyl) group attached to the oxadiazole ring, and a 4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl group linked to the oxadiazolinone ring. 1,2,4-Oxadiazol-5(4H)-one, 4-(3-bromo-4-fluorophenyl)-3-[4-[(2-methoxyethyl)amino]-1,2,5-oxadiazol-3-yl]- may have potential applications in medicinal chemistry, as oxadiazole derivatives are known for their diverse biological activities, including antimicrobial and anticancer properties. The presence of both oxadiazole and oxadiazolinone moieties in this compound could potentially contribute to its biological activity and make it a promising candidate for further research and development.

Upstream product

• 1204669-62-4 N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[(2-methoxyethyl)amino]-1,2,5-oxadiazole-3-carboximidamide 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1204669-62-4 N-(3-bromo-4-fluorophenyl)-N‘-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-61-3 N-hydroxy-4-[(2-methoxyethyl)amino]-1,2,5-oxadiazole-3-carboximidoyl chloride 
• 1204669-60-2 N¹-hydroxy-4-((2-methoxyethyl)amino)-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-59-9 4-amino-N‘-hydroxy-N-(2-methoxyethyl)-1,2,5-oxadiazole-3-carboximidamide 

Downstream Products

• 1204669-64-6 4-(3-bromo-4-fluorophenyl)-3-{4-[(2-hydroxyethyl)amino]-1,2,5-oxadiazol-3-yl}-1,2,4-oxadiazol-5(4H)-one 
• 1204669-37-3 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N’-hydroxy-1,2,5-oxadiazole-3-carboximidamide 
• 1204669-65-7 2-({4-[4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}amino)ethyl methanesulfonate 
• 1204669-66-8 3-(4-((2-azidoethyl)amino)-1,2,5-oxadiazole-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazole-5(4H)-one 
• 1204669-68-0 tert‐butyl N‐[2‐({4‐[4‐(3‐bromo‐4‐fluorophenyl)‐5‐oxo‐1,2,4‐oxadiazol‐3‐yl]‐1,2,5‐oxadiazol‐3‐yl}amino)ethyl]carbamate 
• 1204669-67-9 3‐{4‐[(2‐aminoethyl)amino]‐1,2,5‐oxadiazol‐3‐yl}‐4‐(3‐bromo‐4‐fluorophenyl)‐1,2,4‐oxadiazol‐5‐one hydrochloride 
• 1204669-69-1 (Ν-(2-((4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-yl)amino)ethyl)tert-butylsulfamoyl)carbamate 
• 1204669-70-4 N-[2-({4-[4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]-1,2,5-oxadiazol-3-yl}amino)ethyl]sulfamide 
• 1888341-29-4 4-(3-bromo-4-fluorophenyl)-3-(4-{[2-(methylthio)ethyl]amino}-1,2,5-oxadiazol-3-yl)-4,5-dihydro-1,2,4-oxadiazol-5-one 

Relevant articles and documents

INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION

The present invention relates to an indoleamine 2,3-dioxygenase inhibitor having the structure of formula (I), a preparation method therefor, and an application. The IDO inhibitor is an N′-hydroxyl-N-phenylformamidine derivative, which has a high inhibito

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE

Provided are compounds of formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the prog